Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity.
BB-1701 是一种靶向 HER2 的含艾立布林的抗体药物偶联物 (ADC),具有强大的旁观者效应和 ICD 活性,其临床前研究
期刊:Antibody Therapeutics
影响因子:4.5
doi:10.1093/abt/tbae019
Wang Yang, Xia Bing, Cao Lixia, Yang Jianfeng, Feng Cui, Jiang Fangdun, Li Chen, Gu Lixia, Yang Yifan, Tian Jing, Cheng Xin, Furuuchi Keiji, Fulmer James, Verdi Arielle, Rybinski Katherine, Soto Allis, Albone Earl, Uenaka Toshimitsu, Gong Likun, Liu Tingting, Qin Qiuping, Wei Ziping, Zhou Yuhong